$HRTX, The Heron Therapeutics Inc (HRTX) Earns Buy

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
545
$HRTX,

The Heron Therapeutics Inc (HRTX) Earns Buy Rating from Analysts at Needham & Company LLC
March 10, 2017 Darlene McCollum
The Heron Therapeutics Inc (HRTX) Earns Buy Rating from Analysts at Needham & Company LLC

Needham & Company LLC started coverage on shares of Heron Therapeutics Inc (NASDAQ:HRTX) in a research note published on Monday. The brokerage issued a buy rating and a $28.00 price target on the biotechnology company’s stock.

A number of other brokerages also recently issued reports on HRTX. JMP Securities reaffirmed a buy rating on shares of Heron Therapeutics in a research report on Wednesday, November 9th. Jefferies Group LLC set a $29.00 target price on shares of Heron Therapeutics and gave the stock a buy rating in a research note on Thursday, January 5th. Cantor Fitzgerald reiterated an overweight rating and issued a $34.00 target price on shares of Heron Therapeutics in a research note on Friday, January 6th. Cowen and Company reiterated a buy rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Sunday, December 11th. Finally, Zacks Investment Research cut shares of Heron Therapeutics from a hold rating to a sell rating in a research note on Tuesday, January 10th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $36.22.

Heron Therapeutics (NASDAQ:HRTX) traded down 1.37% during mid-day trading on Monday, hitting $14.40. 596,714 shares of the stock were exchanged. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $25.46. The company has a 50-day moving average of $13.50 and a 200-day moving average of $15.91.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.05. On average, equities analysts forecast that Heron Therapeutics will post ($3.49) EPS for the current year.

In other news, Director Kevin C. Tang bought 2,459,016 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The shares were purchased at an average cost of $12.20 per share, for a total transaction of $29,999,995.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.31% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Heron Therapeutics by 0.4% in the fourth quarter. FMR LLC now owns 5,872,839 shares of the biotechnology company’s stock worth $76,934,000 after buying an additional 20,545 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Heron Therapeutics by 13.4% in the fourth quarter. Janus Capital Management LLC now owns 4,575,807 shares of the biotechnology company’s stock valued at $59,947,000 after buying an additional 542,007 shares in the last quarter. Broadfin Capital LLC raised its position in shares of Heron Therapeutics by 23.8% in the fourth quarter. Broadfin Capital LLC now owns 3,899,587 shares of the biotechnology company’s stock valued at $51,085,000 after buying an additional 749,587 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $49,230,000. Finally, Highland Capital Management LP raised its position in shares of Heron Therapeutics by 140.2% in the fourth quarter. Highland Capital Management LP now owns 1,562,817 shares of the biotechnology company’s stock valued at $20,473,000 after buying an additional 912,086 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 113

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 84

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 62

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 72

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 102

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 28

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading

Top 5 Most Recently Viewed Articles

NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale

Updated Category News Views 195

NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale NANO Nuclear Energy Inc. has made a pivotal move by signing a letter of intent to sell its innovative ODIN™ low-pressure coolant reactor technology. This strategic decision not only signifies NANO Nuclear's commitment to optimizing their technology portfolio but also enables a sharper focus on their...

Continue Reading
Project C.U.R.E. and Microsoft: Transforming Global Health Access

Updated Category News Views 244

Transforming Global Healthcare Through Innovative Partnerships In a world where access to essential healthcare is still a significant challenge, Project C.U.R.E. has teamed up with Microsoft to make a meaningful difference. This collaboration aims to change the lives of millions by providing vital medical resources to underserved populations. With over 4.5 billion people...

Continue Reading
How STRADVISION Is Leading the Charge in Automotive Innovation

Updated Category News Views 395

Transforming the Automotive Industry: STRADVISION's Role STRADVISION, a pioneer in deep learning-based vision perception technology, is at the forefront of a revolution in the automotive industry. Their latest edition of the STRADVISION Market Intelligence Report delves into significant trends transforming the automotive landscape, influenced by advancements in autonomous...

Continue Reading
Holdings and Legal Developments: Atkore Inc. Class Action Insight

Updated Category News Views 182

Understanding the Atkore Inc. Class Action Lawsuit In recent developments, Atkore Inc. (NASDAQ: ATKR) is facing a class action lawsuit that has raised significant attention among investors. The lawsuit, officially titled Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Atkore Inc., highlights serious allegations against the company and its...

Continue Reading
Brenda Snow's Empowering New Book for Patients on Health Journey

Updated Category News Views 279

Brenda Snow's Inspiring Book on Navigating Health Challenges Brenda Snow's upcoming book is generating buzz as a vital resource for individuals grappling with serious health issues. This essential guide, titled Diagnosed: The Essential Guide to Navigating the Patient's Journey, is set to empower patients and caregivers alike. A Personal Narrative That Inspires In her...

Continue Reading